Research programme: anti-TAA monoclonal antibodies - Micromet
Latest Information Update: 19 Mar 2008
At a glance
- Originator Micromet Inc
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 May 2006 Micromet AG has merged with CancerVax Corporation to form Micromet Inc
- 20 May 2004 Preclinical trials in Cancer in USA (Parenteral)